The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1347
Dalfampridine (Ampyra) for MS
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered a reliable clinical measure of impairment in patients with MS.

DRUGS FOR MS — Current treatments for relapsing forms of MS include interferon beta, glatiramer acetate (Copaxone), mitoxantrone (Novantrone) and natalizumab (Tysabri).1 Rituximab (Rituxan) and alemtuzumab (Campath) have also been used off-label for this indication.2 Formulations of 4-aminopyridine prepared by compounding pharmacies have been used in clinical practice in MS patients for several years; anecodotal reports have suggested that they improve motor function and decrease fatigue.

MECHANISM OF ACTION — The exact mechanism ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dalfampridine (Ampyra) for MS
Article code: 1347a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian